Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Ribavirin 4ledipasvir, sofosbuvir drug combination 3sofosbuvir-velpatasvir drug combination 2elbasvir-grazoprevir drug combination 2Sorafenib 2Sofosbuvir 2telaprevir 1rocakinogene sifuplasmid 1pembrolizumab 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1ledipasvir 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Medical Marijuana 1Mass Screening 1Introns 1Immunoglobulin G 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatitis C × grazoprevir × Clear all
NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡